This one has come to my attention after a sudden surge from the bottom of its price range.

In the last two weeks, PURI has announced US FDA approval to market its Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US; also announced first prelims showing increasing business (still losing dough but it has a growing turnover), and prospects of business from US supermarket chains interested in shelf sterilisation kits, and today a small nibble by directors.

Stock is tightly held but you can get a few on SETS if this is your kind of stock. It's shooting up at the moment and there isn't yet much of a following "over the road" which is a good sign for further interest I guess.

FDA RNS of 5/4/07

Preliminary results

This paragraph looked promising:

"Food Safety: By year end, PuriCore had garnered approximately 4% of the market
for US retail supermarkets. The Company completed a national roll-out for a
top-five US supermarket chain and concluded a new, three-year lease agreement
calling for the installation of more than 200 further Sterilox Systems,
generating cumulative revenue and cash flow totalling approximately $3.3
million. Of the approximately 1,400 Systems installed at year end, 88% were
under long-term lease agreements. Several top-10 US supermarket chains are
currently in late-stage trials."

Chart since float last June:

DJ PuriCore Plc Clinical Results for Vashe Wound Therapy

TIDMPURI

RNS Number : 3542C

PuriCore Plc

11 November 2009

?

PuriCore Announces Promising Clinical Results for Vashe Wound Therapy in Post-Operative Care of Skin Grafts on Burns

Cost-effective biocompatible wound treatment shows potential effectiveness in helping ensure graft take

MALVERN, PENNSYLVANIA, and STAFFORD, UK, 11 November 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is a safe, effective, and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.

The clinical trial was conducted by Kevin Foster, MD, MBA, FACS, Co-Director of the Arizona Burn Center at the Maricopa Medical Center in Phoenix, Arizona. Results showed that Vashe Wound Therapy is as effective as the control, 5% Sulfamylon solution (mafenide acetate, USP), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control. The average graft take for Vashe Wound Therapy and 5% Sulfamylon was 97.4% and 96%, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy. Further, the trial showed that Vashe Wound Therapy demonstrated greater than a 50% cost savings compared with 5% Sulfamylon. Dr. Foster presented results of this trial at the Southern Regional Burn Conference on November 7, 2009, in Shreveport, LA.

Dr. Foster, lead clinician, said:

"Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post operative skin graft irrigation while offering significant overall cost savings. This trial also suggests that Vashe has further potential for pain improvement opportunities."

Greg Bosch, Chief Executive, said:

"These clinical results are further evidence that Vashe Wound Therapy is highly effective for wound care, offering an additional boost to the body's own defense and without any cytotoxic effects that can slow the rate of wound healing. With the increasing attention to cost-containment in healthcare, Vashe Wound Therapy offers a new cost-effective alternative to traditional wound irrigants."

About Vashe Wound Therapy

Vashe Wound Therapy is a medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy is biocompatible, non-cytotoxic, and non-mutagenic. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic products currently used to treat infected wounds and post-operative surgical sites and is an important element in the overall plan of care for effective wound management. It is a cost-effective alternative to traditional wound irrigants and is a non-staining solution.

Enquiries:

+--------------------------+--------------------------+
| Ben Brewerton | Greg Bosch, CEO |
| Susan Quigley | Darren Weiss, CFO |
| Financial Dynamics | PuriCore |
| +44 (0) 20 7831 3113 | +1 484 321 2700 |
+--------------------------+--------------------------+

About PuriCore

PuriCore (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H5N1 and H1N1 Influenza), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Vashe and PuriCore are registered trademarks of PuriCore Inc. All other trademarks are property of their respective owners.

This information is provided by RNS

The company news service from the London Stock Exchange

NRACKDKPNBDDADD

(END) Dow Jones Newswires